EGFR and lung carcinoma: The histone deacetylase (HDAC) inhibitor vorinostat promotes ferroptosis through downregulating xCT, resulting in a dramatic increase in hydroperoxides in EGFR-mutant lung cancer cells (Zhang et al., 2021).